Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc. is a biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. Its lead product candidate is TX45, a Fc-relaxin fusion molecule designed to activate the RXFP1 receptor, which is the GPCR target of the hormone relaxin. Additionally, Tectonic is developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia. The company's pipeline also includes a GPCR modulator bispecific for treating fibrosis and other GPCR modulators.

Tectonic Therapeutic, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol TECX. The company's stock is traded in US Dollars (USD), as it is headquartered in the United States and its primary listing is on a US exchange. Investors can buy and sell shares of TECX on NasdaqGM during regular trading hours, with all transactions denominated in USD.

Tectonic Therapeutic, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies that target GPCRs, which are important cell surface receptors involved in many physiological processes. The company's work involves protein engineering and antibody development, placing it at the forefront of biologic drug discovery for conditions such as fibrosis and vascular disorders.

Tectonic Therapeutic, Inc. is headquartered in Watertown, Massachusetts, United States. The company primarily serves the US market, as indicated by its US-based operations and listing on a US exchange. While its research and development activities are centered in the US, the potential therapies it develops could address global healthcare needs, particularly in areas like fibrosis and hereditary hemorrhagic telangiectasia. However, based on available data, the company's current focus is on the US market.

Tectonic Therapeutic's pipeline includes several key product candidates. The lead candidate is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, targeting the GPCR of the hormone relaxin. Another candidate is TX2100, being developed for hereditary hemorrhagic telangiectasia. Additionally, the company is working on a GPCR modulator bispecific for treating fibrosis, as well as other GPCR modulators. These candidates leverage the company's GEODe platform to create biologic medicines that precisely modulate GPCR activity.